| http://www.w3.org/ns/prov#value | - But in Friday's split decision, the U.S. Court of Appeals for the Federal Circuit expanded that safe harbor to any use, including post-approval, that is reasonably related to the development and submission of information under a federal law which regulates the manufacture, use or sale of drugs.The decision sinks the long-held notion that once regulatory approval was granted by the FDA, the safe
|
